Frontline Daratumumab Improves Progression-Free Survival in High-Risk Multiple Myeloma
The addition of daratumumab resulted in a 41% reduction in the risk of disease progression or death.
Multiple Myeloma News
MULTIPLE MYELOMA ADVISOR
Multiple Myeloma News
Elotuzumab Does Not Improve PFS in Newly Diagnosed Multiple Myeloma
Adding elotuzumab to lenalidomide and dexamethasone did not improve any efficacy outcomes.
Risk of Neurologic AEs Lower With Immune Checkpoint Inhibitors Than With Other Cancer Therapies
The risk of neurologic adverse events was 41% lower in patients treated with immune checkpoint inhibitors than in patients who received another drug regimen or a placebo.
Lenalidomide Maintenance Superior to Bortezomib for Myeloma Patients With Abn1q
Among patients with Abn1q, those who received bortezomib-based maintenance had significantly worse progression-free survival and overall survival.
Racial Disparities Noted in Treatment With Bone-Modifying Agents Among Patients With Multiple Myeloma
Researchers sought to determine if there are racial disparities in treatment with bone-modifying agents for patients with multiple myeloma.
Real-World Data Confirm Lack of Standard Care for Triple-Exposed Multiple Myeloma
After triple-class exposure, patients received more than 50 unique treatment regimens.
Most Blood Cancer Drug Trials Are Not Randomized, Use Surrogate Endpoints
Of more than 2500 trials analyzed, 21% were randomized.
Predictors of Mortality During Hospital Stays in Patients With Multiple Myeloma
Researchers sought to determine the predictors of mortality during hospital stays in patients with multiple myeloma.
Cancer Risks, Mortality Vary With CKD Stage
The proportion of patients with chronic kidney disease who die from cancer may be underappreciated.
CAR-T Cells Targeting BCMA and CD19 Produce Durable Responses in Multiple Myeloma
More than 90% of patients achieved a response, and the median duration of response exceeded 20 months.
HDM Remains Standard Conditioning Regimen for Multiple Myeloma
Adding bortezomib to high-dose melphalan did not improve response rates or survival outcomes.
Cancer Is Associated With Increased Kidney Failure Risk
The risk for kidney failure requiring renal replacement therapy varies by cancer type, with multiple myeloma associated with the highest risk.
How Can Multiple Myeloma Affect a Patient’s Lifestyle?
Multiple myeloma (MM) forms in a patient’s plasma cells, and the symptoms it brings can affect their quality of life in ways they may not be thinking about when first diagnosed. What are some lifestyle factors that are affected by multiple myeloma, and how can you discuss managing them with your patients?
Drugs in Phase 1 Trials Becoming More Effective, No Less Fatal
Response rates improved from 2000 to 2019, but the rate of treatment-related fatal toxicities remained stable.
Moderna COVID-19 Vaccine ‘Preferred’ for Patients With Multiple Myeloma
Rates of SARS-CoV-2 neutralizing antibodies are significantly higher with the Moderna vaccine than with the Pfizer-BioNTech vaccine in patients with multiple myeloma.
Negative PET/CT at 6 Months Tied to Longer Survival in Multiple Myeloma
The median time to next treatment and overall survival were longer in patients with a negative PET/CT at 6 months post-induction.
Low Serum Complement C4 Predicts Poorer Outcomes in Newly Diagnosed MM
Researchers sought to confirm an association between serum complement C4 levels and outcomes in patients with newly diagnosed multiple myeloma.
Novel Approaches for Monitoring Multiple Myeloma Using cfDNA, Circulating Plasma Cells
Two novel analytical approaches can accurately indicate the course of multiple myeloma, according to researchers.
Isatuximab May Provide Long-Term Benefit in Relapsed/Refractory Multiple Myeloma
Isatuximab prolonged progression-free survival and time to next treatment.
MRD Status Appears to Predict PFS in Multiple Myeloma
Achieving a CR with MRD negativity was linked to improved PFS, regardless of the treatment received or the disease setting.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma News
Loading... 
Loading...